deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01543698

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

A Phase Ib/II, Multicenter, Open-label, Dose Escalation Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors

Sponsor: Pfizer

Conditions Solid Tumors Harboring a BRAF V600 Mutation
Interventions LEE011 LGX818 MEK162
Updated 25 times since 2017 Last updated: Feb 15, 2024 Started: May 28, 2012 Primary completion: Mar 9, 2023 Completion: Mar 9, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Solid Tumors Harboring a BRAF V600 Mutation and is currently completed. Pfizer leads this study, which shows 25 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Mar 2018 · 12 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~May 2019 · 7 months · monthly snapshot~May 2019 – ~May 2020 · 12 months · monthly snapshot~May 2020 – ~Oct 2020 · 5 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jun 2021 · 4 months · monthly snapshot~Jun 2021 – ~Nov 2021 · 5 months · monthly snapshot~Nov 2021 – ~Feb 2022 · 3 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Nov 2022 · 7 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~May 2023 · 3 months · monthly snapshot~May 2023 – ~Aug 2023 · 3 months · monthly snapshot~Aug 2023 – ~Apr 2024 · 8 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

25 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Apr 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Aug 2023 — Apr 2024 [monthly]

    Completed PHASE1_PHASE2

▶ Show 20 earlier versions

  1. May 2023 — Aug 2023 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  2. Feb 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Jan 2023 — Feb 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Nov 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Apr 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Feb 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Nov 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Jun 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Phase: PHASE2 → PHASE1_PHASE2

  10. Feb 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE2

    Phase: PHASE1_PHASE2 → PHASE2

  11. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  12. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  13. May 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  14. May 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  15. Oct 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  16. Jun 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  17. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  18. Mar 2017 — Mar 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  19. Feb 2017 — Mar 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  20. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Barcelona, Spain , Boston, United States , Camperdown, Australia , Houston, United States , Leuven, Belgium , Madrid, Spain , Milan, Italy , Montreal, Canada , Naples, Italy and 9 more locations